Member Info for Superda

Director’s comments that SP way undervalued !

https://youtu.be/PAGEb2UBpzo?si=eUDKUxYlBebcDFAS

Director’s buy coming in or bid ?

As news flowing in, I think the SP reversal has started. Zak predicted 8 short term and with more news on CIC fda approval SP likely to go back to 25 and higher.

https://www.medicaldevice-network.com/news/uk-nice-backs-use-of-genincodes-test-for-ovarian-cancer-surveillance/

GLA

Octopus increased their holding over 16% in January. They must have done their due diligence on Geni’s projects.

CIC’s fda approval seems to be sure shot considering that it’s a unique polygenic, patended in-vitro diagnostic test used to assess an individuals inherited (DNA) genetic risk of Coronary Heart Disease. The test is based on published clinical evidence amassed over the past 15 years and combined with traditional clinical risk provides a comprehensive risk assessment of Cardiovascular Disease (CVD) for use in primary preventative care.

Still cheap to get in. I would say get in and hold and we will be rewarded, in my view.

Not just in terms of making profit on our investments; it will be a breakthrough in managing future heart care management!

GLA

I know. It’s fully understandable to keep such things secret at this time to avoid market fluctuations. It’s just my curiosity 😊

From what I have read and seen so far, I don’t have any issue in trusting Geni. I strongly believe it’s going to be a game changer !

GLA

As we know from RNS dated 19/07/23, Geni is working in partnership with Medstar heath in US trialing CIC. I was looking for updates, but can’t find much info. I have seen a link about them opening clinics, but I can’t open the link.

https://www.baltimoresun.com/2024/03/04/medstar-patient-centered-focus-cardiovascular-outpatient-center/

I think we may get to see a TR1 soon. It’s a no brainier for a big player to get in at this time.

You are correct. No point in selling; you will have to pay lot higher to get back in. This is a golden ticket. News spreading out and with low free flout this is going to rocket! GLA

🚀 Quietly climbing up as everyone predicted !

Hope this gets to 8.1 quick and then the FDA news to rocket to the moon 🚀🚀🚀🚀

GLA

Zak predicts 8.1 short term

https://youtu.be/mugBaGF0u_M

My view is that, it’s not a dream or guess anymore. The NICE assessment/ recommendation of ROCA is just the beginning. In terms of CIC-Score, FDA’s initial assessment was that it’s ‘first in class' position and have deep clinical evidence for polygenic risk assessment of CHD’. Hence, asked to submit under De Novo pathway.

As you may know, The De Novo request provides a marketing pathway to classify novel medical devices for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device.

Bright days ahead in my view 🙌

GLA

Momentum building. Geni all over the media with news from yesterday.

https://www.medicaldevice-network.com/news/uk-nice-backs-use-of-genincodes-test-for-ovarian-cancer-surveillance/

Hope we will get to see the FDA approval news on Monday ! GLA

Was checking SP movements; when Geni received California state licensing approval and CLIA, SP went from 7.5 to 24 !

IMHO get in and hold, this is about to rocket anytime!

GLA

Buyout is highly likely, especially with FDA’s initial assessment as ‘first in class' position and the deep clinical evidence for polygenic risk assessment of CHD’.

Huge potential!

Huge re-rate chances here 🚀🚀🚀🚀🚀

FDA approval news due anytime. See below from RNS dated

Following the CARDIO inCode-Score 510(k) medical device submission in August 2023, the FDA has reviewed the submission and recently noted CARDIO inCode-Score's 'first in class' position and the deep clinical evidence for polygenic risk assessment of CHD. Based on these factors and the novel position of CARDIO inCode-Score, the FDA has requested the Company to transition to a De Novo pathway for market approval. The crossover to a De Novo pathway enables the Company to work with the FDA to establish a new polygenic regulatory class for the CARDIO inCode-Score medical device based on its favourable benefit-risk profile and associated special controls thereby setting a new regulatory standard for future polygenic tests in this class. Following the FDA request, the Company has now submitted its De Novo submission for market clearance and expects a timeline to clearance broadly in line with earlier the earlier 510(k) submission forecasts of late Q1/early Q2 2024.

First US revenue news also due !

Check the link below; found on X

https://x.com/buoyant_recluse/status/1770816631490462110?s=46&t=WuyCAqCnuctRxVwyXpOFyg

Warming up nicely! GLA 🙌

GENinCode says ROCA recommended as ovarian cancer risk test in England

https://www.marketscreener.com/quote/stock/GENINCODE-PLC-125090824/news/GENinCode-says-ROCA-recommended-as-ovarian-cancer-risk-test-in-England-46252319/

Also, FDA approval news on CARDIO inCode-Score 510(k) is due anytime !

Best time to get in ! With good cash position and revenue it’s going to fly soon ! Can see that this was 19 a year ago.

GLA

News soon. People taking positions on both side !

https://www.londonstockexchange.com/news-article/market-news/holding-s-in-company/16387119

News very soon I think !

GLA

Get your facts right @petro, deramper ! DKE is looking for r takeover company. From the recent TR1, it looks like we have one in place. It’s just a matter of time for this to rerate. Derampers trying to scare you to get your shares cheap !

GLA genuine holders.

RSI back on 14, this will fly again soon !

Remember this was 7.50 not that long ago. GLA

Future CoalSwitch® production.

Since September 2023, Active Energy has focused on improvements to both CoalSwitch® fuel and the production processes utilizing the new executive management team based in the US. At the Interim Results, the Company announced a working partnership with Omega Thermal Solutions Group LLC, based in the US, to develop a new manufacturing process and create variants of CoalSwitch® fuel focusing on a torrefaction production process. The improved fuel performance metrics, such as higher fixed carbon content allows these biocarbon fuels to participate in the growth markets such as soil amendments, air filtration, ferro silicon and the metallurgical steel industries. This product development is opening new revenue opportunities for CoalSwitch®. From RNS dated 05/03/24.

Check the link below, good read

https://www.sciencedirect.com/science/article/pii/S2589014X24000124?dgcid=rss_sd_all